{"id":"W4306774464","doi":"10.1016/j.ymthe.2022.09.020","title":"First conditional marketing authorization approval in the European Union for hemophilia “A” gene therapy","year":2022,"lang":"en","type":"editorial","venue":"Molecular Therapy","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"Canadian Hemophilia Society","funders":"","keywords":"Factor IX; Medicine; Haemophilia; Genetic enhancement; Clotting factor; Haemophilia B; Haemophilia A; Marketing authorization; Coagulation; Internal medicine; Pediatrics; Bioinformatics; Gene; Genetics; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009189946,0.001926092,0.002662081,0.001546889,0.002423133,0.00640985,0.002732209,0.03203415,0.01140587],"category_scores_gemma":[0.02081484,0.0008954881,0.002469787,0.0007309835,0.002739055,0.002956131,0.001082921,0.02706337,0.006917979],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003691534,"about_ca_system_score_gemma":0.004163143,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002620558,"about_ca_topic_score_gemma":0.006252025,"domain_scores_codex":[0.995097,0.001153871,0.0004085308,0.0005018684,0.002350861,0.0004878245],"domain_scores_gemma":[0.9864248,0.007885694,0.0006414445,0.0003521676,0.003079577,0.001616287],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000061336,0.00002114668,0.00002017515,0.0001329107,0.00002634813,0.0002084878,0.00001055211,0.00002641712,0.0001453586,0.000983111,0.9935558,0.004808248],"study_design_scores_gemma":[0.0001490131,0.00004404836,0.0003484404,0.0002721325,0.00007162626,0.00022951,0.00002340111,0.0001744106,0.0002587138,0.001649931,0.9967557,0.00002321013],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.0001825837,0.01032393,0.0004006847,0.08883291,0.8896378,0.00004710882,0.0001127727,0.0001179345,0.01034421],"genre_scores_gemma":[0.003512148,0.008294376,0.000560265,0.1488295,0.7834182,0.00008310876,0.0001114379,0.0001378195,0.05505318],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.03203415,"threshold_uncertainty_score":0.04860169,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01582316216343343,"score_gpt":0.2883382761039605,"score_spread":0.272515113940527,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}